X

Trial Profile

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

Most Recent Events

12 Dec 2023 Results assessing efficacy and safety of nanobody-based anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
25 Sep 2020 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
25 Sep 2020 Planned primary completion date changed from 30 Aug 2020 to 30 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com